Targeted Genetic Testing (TGT)
3X Genetics operates a licensed genetic testing laboratory. We seek to improve lives by accelerating the diagnosis and treatment of genetic diseases, starting with Repeat Expansion Diseases (REDs.) REDs are common and often misdiagnosed. Currently, there are 69 known REDs, including Myotonic Dystrophy, Fuchs Endothelial Corneal Dystrophy (FECD), Friedreich’s Ataxia (FA), Huntington’s Disease, Fragile X, and Spinocerebellar Ataxias (SCAs). The good news is that therapeutics are emerging and 3X Genetics is developing a TGT platform to analyze drug efficacy and accurately diagnose RED diseases.
Our services support BioPharma companies and their patients.
3X Genetics currently offers TGT services for REDs, including Myotonic Dystrophy and Fuchs Endothelial Corneal Dystrophy (FECD.) The 3X-TGT Platform helps BioPharma companies discover patients and measure drug efficacy. 3X-TGT exploits the convergence of biotechnology and machine learning (AI) to produce high-accuracy DNA sequencing results at a low-cost.
3X Genetics Inc. 17 Briden Street, Suite 105, Worcester, MA 01605
(c) 3X Genetics Inc. 2024